You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care

Hooshyar, Dinaa,b; Napravnik, Soniaa; Miller, William Ca,b; Eron, Joseph J Jra

AIDS:
doi: 10.1097/01.aids.0000210612.37589.12
Clinical Science
Abstract

Objectives: To estimate the effect of hepatitis C (HCV) coinfection on time to first occurrence of either discontinuation or modification of initial HAART among previously antiretroviral therapy-naive HIV-infected patients.

Methods: The analysis included antiretroviral therapy-naive patients who initiated HAART prior to November 2003 and were participating in the University of North Carolina Center for AIDS Research, HIV/AIDS observational clinical cohort. The effect of HCV status on time to first occurrence of either HAART discontinuation or modification was assessed using Kaplan–Meier survival estimates and multivariable proportional hazards regression was used to estimate hazard ratios.

Results: Of 296 patients initiating HAART, 22% were coinfected with HCV. During a median follow-up of 473 days [interquartile range (IQR), 167–940] from HAART initiation, 104 (35%) patients discontinued and 91 (31%) modified their first regimen. Reasons for discontinuation and modification were comparable by HCV serostatus and included treatment failure (12%), toxicity (41%), and barriers to adherence (47%). The median time to first occurrence of either discontinuation or modification among HCV-infected patients was 401 days (IQR, 128–821), and among HCV-uninfected patients was 493 days (IQR, 204–952) (P = 0.22). After adjustment for baseline demographic and clinical characteristics, the hazard ratio contrasting HCV-infected with HCV-uninfected patients was 1.39 (95% confidence interval, 0.95–2.03; P = 0.09).

Conclusion: HCV coinfection was only marginally associated with a shorter duration of an initial HAART regimen, suggesting optimization of a first HAART regimen may not appreciably depend on HCV serostatus.

Author Information

From the aDivision of Infectious Diseases, School of Medicine

bDepartment of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Received 15 July, 2005

Revised 27 October, 2005

Accepted 3 November, 2005

Correspondence to S. Napravnik, Division of Infectious Diseases, University of North Carolina at Chapel Hill, 211A W Cameron St CB 7215, Chapel Hill, North Carolina 27599–7215, USA. E-mail: napravs@med.unc.edu

© 2006 Lippincott Williams & Wilkins, Inc.